January 30, 2024
Astellas Pharma and Pfizer said that European regulators on January 26 accepted for review an application seeking approval for the frontline bladder cancer use of their antibody drug conjugate Padcev (enfortumab vedotin) together with Merck’s PD-1 inhibitor Keytruda (pembrolizumab). The...read more